© 2001 European Society of Cardiology
Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis
Department of Medicine and Therapeutics, University of Leicester Leicester, UK
* Corresponding author. Department of Medicine and Therapeutics, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK. Tel.: + 1-116-252-3126; fax: + 1-116-252-3108. E-mail address: lln1{at}le.ac.uk (L.L. Ng)
 |
Abstract |
|---|
Background: Echocardiography with Doppler examination of the aortic valve provides a very accurate assessment of the transvalvular gradient and is used to monitor progression of aortic stenosis (AS). Plasma brain natriuretic peptide (BNP) has been shown to correlate with end-systolic wall stress in patients with AS.
Aim: We hypothesized that plasma N-terminal proBNP (NT proBNP) and a newly identified cytokine cardiotrophin-1 (CT-1), which has been shown to stimulate BNP production at a transcriptional level are elevated in patients with AS and correlate to the maximum trans-valvular aortic pressure gradient (TVPG).
Method: We compared plasma NT proBNP and CT-1 in 15 AS patients [five males, mean age 79 years [range 60–94], mean TPVG 39.3 mmHg (20–100)] with 10 controls (five male, mean age 68 years [56–79]). Results are expressed as mean [ranges] and comparisons were by the Mann–Whitney test.
Results: NT proBNP levels were elevated in AS patients [252.9 fmol/ml (79.2–541.8)] when compared with the controls (157.2 fmol/ml [104.7–236.9], P < 0.005). Also CT-1 levels were elevated in AS patients (57.3 fmol/ml [33–86.3] when compared with the controls [28.3 fmol/ml (6.9–48.3), P < 0.0005]. Both NT proBNP and CT-1 levels were correlated to the TVPG (r = 0.53 and r = 0.65, P < 0.05 and P = 0.009, respectively). On best subset analysis the strongest correlate with TVPG was CT-1 (R2 = 38%). The addition of NT proBNP did not improve diagnostic accuracy (R2 = 39%).
Conclusion: These results suggest NT proBNP and CT-1 levels increase in proportion to the TVPG and could potentially be used to monitor progression of disease non-invasively. These markers may also be useful to identify the optimum time for surgery in AS.
Key Words: Aortic stenosis • Brain natriuretic peptide • Cardiotrophin-1 • Echocardiography
Received July 16, 1999; Revised January 14, 2000; Accepted February 17, 2000
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. Hausenloy and D. M. Yellon Cardioprotective growth factors Cardiovasc Res, July 15, 2009; 83(2): 179 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland and K. Goode Natriuretic peptides for heart failure. Fashionable? Useful? Necessary? Eur J Heart Fail, March 15, 2004; 6(3): 253 - 255. [Full Text] [PDF]
|
|
|
|
|
|
R. J. O'Brien, I. B. Squire, B. Demme, J. E. Davies, and L. L. Ng Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF Eur J Heart Fail, August 1, 2003; 5(4): 499 - 506. [Abstract] [Full Text] [PDF]
|
|